<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>ijcicr</PublisherName>
<JournalTitle>International Journal of Clinical Investigation and Case Reports</JournalTitle>
<PISSN>C</PISSN>
<EISSN>l</EISSN>
<Volume-Issue>Volume 1, Issue 2</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>(Aug-Oct)</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2022</Year>
<Month>09</Month>
<Day>9</Day>
</PubDate>
<ArticleType>Genetics</ArticleType>
<ArticleTitle>Epithelial Growth Factor Receptor Mutations Predict Hepatocellular Carcinoma Patient’s Prognosis</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>45</FirstPage>
<LastPage>51</LastPage>
<AuthorList>
<Author>
<FirstName>Lo Wei-Ching</FirstName>
<LastName/>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Jung-Sheng Chen</FirstName>
<LastName/>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Wen-Chi Yang* (TAIWAN)</FirstName>
<LastName/>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI>10.55828/ijcicr-12-09</DOI>
<Abstract>Objective: Hepatocellular Carcinoma (HCC) is an aggressive malignancy and the second leading cause of cancer-related death in the world. Epithelial Growth Factor Receptor (EGFR) overexpression has been demonstrated in HCC patients frequently and is a poor prognostic factor. EGFR is a promising target for cancer treatment, but its variety in response by mutation status.
Patients and Methods: We retrospective analyzed 28 Hepatocellular Carcinoma (HCC) patients with good quality DNA samples, 5 hepatic dysplasia tissues, and 5 cholangiocarcinoma samples from 1996 to 2002. EGFR mutation status was detected by ARMS and Scorpions real-time PCR, using therascreen® EGFR RGQ PCR Kit. T790M, exon 19 deletions, L858R, L861Q, G719X, S786I, and exon 20 insertions can be detected. Clinical data of 28 HCC patients were collected for the longest period of 17 years.
Results: All patients received liver segmentectomy. No one received tyrosine kinase inhibitor treatment during the following period. All liver samples had T790M mutation detected. Based on overall survival, we calculated cut-off points, by ROC curve. In HCC patients with a higher percentage of T790M or G719X mutations had better overall survival (P=0.001, and 0.036). Patients with exon 19 deletion showed a trend of better overall survival. HCC patients with exon 19 deletions, L858R and G719X mutations showed trends of longer Disease Free Survival (DFS) and HCC patients with higher S768I mutation had a trend of shorter DFS. HCC samples from chronic hepatitis B carriers had a higher T790M mutation rate and the ones from chronic hepatitis C carriers showed the opposite in T790M mutation with statistics significant (P=0.013). No EGFR mutations contribute to HCC recurrence.
Conclusion: EGFR mutation status can predict HCC patient’s prognosis post liver segmentectomy.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Hepatocellular Carcinoma ,Cholangiocarcinoma,EGFR,T790M Mutation ,G719X Mutation</Keywords>
<URLs>
<Abstract>https://ijcicr.com/ubijournal-v1copy/journals/abstract.php?article_id=14090&title=Epithelial Growth Factor Receptor Mutations Predict Hepatocellular Carcinoma Patient’s Prognosis</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978 -2012. Int J Cancer. 2020;147(2):317-330.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71 (3):209-249.
Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma casese attributable to major risk factors. Eur J Cancer Prev. 2018; 27(3):205-212.
Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Review. Oncogene. 2010;29(36):4989-5005.
Daveau M, Scotte M, Francois A, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog. 2003;36(3):130-141.
Zhao YN, Cao J, Wu FX, et al. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai Zheng. 2004;23(7):762-766.
Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377-1383.
Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20
Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997;17(4):177-182.
DeCicco LA, Kong J, Rnger DP. Carcinogen-indeced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Lett. 1997;111(1-2):149-156.
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011;12(8):735-42.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int. 2015;2015:171845.
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, as inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med. Assoc. 2003;290(16):2149-2158.
Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2004;84(10):1377-1383.
Altimari A, Fiorentino M, Gabusi E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35(3):332-338.
Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730-734.
Su MC, Lien, HC, Jeng YM. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett. 2005; 224(1):117-121.
Lee SC, Lim SG, Soo R, et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics. 2006;16(1):73-74.
Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation test utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012;23(11):2914-2919.
Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 2006;6(1):1-5.
Bartholomew C, Eastlake L, Dunn P, Yiannakis D. EGFR targeted therapy in lung cancer; an evolving story. Respir Med Case Rep. 2017;20:137-140.
Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE. 2007;2(8):e810.
Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11(3):217-227.
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167-179.
Tang X, Varella-Garcia M, Xavier AC, et al. EGFR Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Cancer Prev Res (Phila). 2008;1(3):192-200.
Han C, Liao X, Qin W, et al. EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma. Sci Rep. 2016;6:31237.</References>
</References>
</Journal>
</Article>
</ArticleSet>